Products & Services
For Academic Researchers
Unlocking new possibilities in cancer research
Foresight CLARITY™ MRD detection helps answer the most pressing questions in cancer research. With decades of experience in liquid biopsy development and translation, our team offers flexible research partnerships to push patient care forward.
Featured research
Learn more about our partners’ innovative research and applications using Foresight CLARITY™ MRD
Memorial Sloan Kettering is researching the potential application of MRD to predict post-adjuvant outcomes in early-stage NSCLC
NIH demonstrated MRD to be more accurate than PET/CT for frontline treatment response in DLBCL
Stanford University and Samsung Medical Center presented the potential for MRD to adjudicate false negative and false positive PET/CT
Raising the standard by lowering limits of detection
Foresight CLARITY™ is powered by PhasED-Seq™, our ultra-sensitive, patented, and peer-reviewed phased-variant detection technology. PhasED-Seq™ monitors patient- and tumor-specific phased variants (PVs), which are two or more single nucleotide variants (SNVs) that occur on the same DNA molecule. Utilizing PVs greatly reduces the background noise/error rate, allowing us to deliver a highly accurate MRD test.
Foresight CLARITY™ for Investigator Initiated Research
Foresight Diagnostics is excited to continue our partnerships with academic and research institutions to further our understanding of MRD and its clinical applications. Submit your inquiry to access Foresight CLARITY™ in your upcoming Investigator Initiated Research.
